Colorectal cancer patients with CASK promotor heterogeneous and homogeneous methylation display different prognosis

Ying Liu,Hao Huang,Jinming Fu,Yuanyuan Zhang,Jing Xu,Lei Zhang,Simin Sun,Liyuan Zhao,Ding Zhang,Justina Ucheojor Onwuka,Hongru Sun,Binbin Cui,Yashuang Zhao
DOI: https://doi.org/10.18632/aging.103928
2020-10-28
Aging
Abstract:Homogenous DNA methylation clearly affects clinical outcomes. However, less is known about the effects of heterogeneous methylation. We aimed to investigate the different effects between <i>CASK</i> promoter methylation heterogeneity and homogeneity on colorectal cancer (CRC) patients' prognosis. The methylation status of <i>CASK</i> in 296 tumor tissues and 255 adjacent normal tissues were evaluated using Methylation-sensitive high-resolution melting (MS-HRM). Digital MS-HRM (dMS-HRM) visualized heterogeneous methylation and subsequent sequencing provided exact patterns. Log-rank test and Cox regression model were adopted to assess the association between <i>CASK</i> methylation status and CRC prognosis with propensity score (PS) method to control confounding biases. Heterogeneous methylation was detected in both tumor (52.2%) and non-neoplastic tissue surrounding the tumor (62.4%). It occurred more frequently in lower levels of tumor invasion (<i>P</i> = 0.002) and male patients (<i>P</i> &lt; 0.001). Compared with heterogeneous methylation, patients with <i>CASK</i> homogeneous methylation presented poorer overall survival (OS) (HR: 1.919, 95% CI: 1.146-3.212, <i>P</i> = 0.013) and disease-free survival (DFS) (HR: 1.913, 95% CI: 1.146-3.194, <i>P</i> = 0.013). This unfavorable effect still existed among older (≥ 50), Dukes staging C/D, and rectal cancer patients. MS-HRM and dMS-HRM when combined can assess the degree and complexity of heterogeneous methylation with a visible pattern.
What problem does this paper attempt to address?